40180-81-2

Usage

Physical state

colorless liquid

Odor

faint

Usage

building block in organic synthesis, pharmaceutical research, and as a solvent and intermediate in the manufacturing of fragrance and flavor compounds

Derivation

bromination of 4-methylacetophenone

Importance

important intermediate in the production of various pharmaceuticals, agrochemicals, and organic compounds

Industry applications

chemical and pharmaceutical industries.

Upstream product

• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 1389311-90-3 C₁₀H₁₂BrCl 
• 147962-81-0 ethyl 3-bromo-4-methylbenzoate 
• 676-58-4 methylmagnesium chloride 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 75-16-1 methylmagnesium bromide 
• 2437-76-5 2-bromo-p-cymene 

Downstream Products

• 40180-82-3 2-bromo-1-methyl-4-(prop-1-en-2-yl)benzene 
• 1345961-02-5 2-(3-bromo-4-methylphenyl)propan-2-ol 
• 1389311-90-3 C₁₀H₁₂BrCl 

Relevant academic research and scientific papers

BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS

The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound.

Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis

Optimization of a benzimidazolone template for potency and physical properties revealed 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as a key template on which to develop a new series of mGlu2 positive allosteric modulators (PAMs). Systematic invest

HETEROCYCLIC DERIVATIVES AND USE THEREOF

A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated

Solvolysis of 2-chloro-2(3,4-disubstituted) phenylpropanes: Validity of Hammett-Brown σ+ constants in assessing additive effects of substituents

The objective of this study is to test the suitability of the extended Hammett-Brown equation, log (kXX/kHH) = ρ+∑σ+, in depicting satisfactorily additive effects of electronegative atom-bearing substituents, which are known to possess diverse and multicomponent influences on the side chain reactions of polysubstituted benzenes. The equation has been used to correlate, for the first time, the additive effect of substituents in the specific rates of solvolysis of 2-chloro-2-phenylpropanes (3b-3f) having 3-F,4-Me, 3-Br,4-Me, 3-I,4-Me, 3-Me,4-Me, or 3-MeO,4-Me substituents. The rates were determined titrimetrically at 288, 298, and 308 K using 90% aqueous acetone as solvent. Measured additive effects of these substituents on the solvolysis rate and activation parameters of the parent cumyl chloride (2-chloro-2-phenylpropane) are found to be well correlated using the equation given above. Plots of log (kXX/k HH) of 3b-3f together with mainly di-, but also tri- and mono-substituted cumyl chlorides from previous studies against ∑σ+ give a linear correlation coefficient of 0.990 as a measure of the validity of the equation to depict such systems. The halogen substituents' extent of conformity with additivity reflected in their relative (kobsd/kcalcd) rate ratios is found to correlate with the steric size of substituents. Plots of rate ratios against Taft's steric factor of each halogen give a linear correlation coefficient of 0.994 for the 3-halo substituents. The 3,4-dimethyl substituents' relative rate ratio of 1.03 shows excellent additivity, whereas the 3-methoxy-4-methyl ratio of 1.43 shows the methoxy group to be far less deactivating than predicted. Similar trends were found for the free energy of activation (δG? - δG 0?) differences, which correlated linearly with a coefficient of 0.983 with Taft's steric factor of halogen atoms.

Design, synthesis and in vivo anti-hyperglycemic activity of gem-dimethyl-bearing C-glucosides as SGLT2 inhibitors

A series of gem-dimethyl-bearing C-glucosides were designed and synthesized as SGLT2 inhibitors, with anhydrous aluminum chloride-mediated Friedel-Crafts alkylation to construct the gem-dimethyl functionality being the key step. The in vivo anti-hyperglycemic activity was evaluated with mice oral glucose tolerance test (OGTT), and all the synthesized compounds showed significant but less potent anti-hyperglycemic activity than the positive control dapagliflozin.

SUBSTITUTED 1,3-BENZOTHIAZOL-2(3H)-ONES AND [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2

The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

POSITIVE ALLOSTERIC MODULATORS OF MGLUR2

The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.